Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Outubro 2023 - 5:00PM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company developing STAR-0215 for the treatment of hereditary
angioedema and focused on life-changing therapies for rare and
niche allergic and immunological diseases, granted stock options to
purchase 61,000 shares of Astria’s common stock on October 2, 2023
under Astria’s 2022 Inducement Stock Incentive Plan. The 2022
Inducement Stock Incentive Plan is used exclusively for the grant
of equity awards to individuals who were not previously an employee
of Astria.
The options were granted as an inducement material to three
employees entering into employment with Astria in accordance with
Nasdaq Listing Rule 5635(c)(4). The options have an exercise price
of $7.06, which is equal to the closing price of Astria’s common
stock on October 2, 2023 (the “Grant Date”), and will vest over a
four-year period, with 25% of shares vesting on the first
anniversary of the employee’s employment start date (which preceded
the Grant Date) and the remaining shares vesting monthly on a
ratable basis over the following 36 months, subject to the
employee’s continued employment with Astria on such vesting dates.
The options are subject to the terms and conditions of the 2022
Inducement Stock Incentive Plan and the terms and conditions of an
award agreement covering the grant.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by rare and niche allergic and immunological
diseases. Our lead program, STAR-0215, is a monoclonal antibody
inhibitor of plasma kallikrein in clinical development for the
treatment of hereditary angioedema. Learn more about our company on
our website, www.astriatx.com, or follow us on Twitter and
Instagram @AstriaTx and on Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231003628986/en/
Investor Relations and Media: Elizabeth Higgins
investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024